UT-MD Anderson Cancer Center: ASCO - Axi-Cel Significantly Improves Survival in Patients With Early Relapsed or Refractory Large B-Cell Lymphoma
June 06, 2023
June 06, 2023
CHICAGO, Illinois, June 6 (TNSjou) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 5, 2023:
* * *
Phase III ZUMA-7 trial finds CAR T cell therapy lowers risk of death by 27.4% compared to standard therapy
* * *
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtage . . .
* * *
Phase III ZUMA-7 trial finds CAR T cell therapy lowers risk of death by 27.4% compared to standard therapy
* * *
Patients with early relapsed or refractory large B-cell lymphoma had significantly improved overall survival when treated with the chimeric antigen receptor (CAR) T cell therapy axicabtage . . .